UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
19.91
-0.55 (-2.69%)
At close: Mar 9, 2026, 4:00 PM EDT
19.80
-0.11 (-0.55%)
After-hours: Mar 9, 2026, 5:11 PM EDT
UroGen Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 109.79 | 90.4 | 82.71 | 64.36 | 48.04 | Upgrade
|
| Revenue Growth (YoY) | 21.45% | 9.29% | 28.52% | 33.96% | 307.17% | Upgrade
|
| Cost of Revenue | 12.45 | 8.88 | 9.36 | 7.65 | 5.16 | Upgrade
|
| Gross Profit | 97.34 | 81.52 | 73.35 | 56.7 | 42.89 | Upgrade
|
| Selling, General & Admin | 155.1 | 122.25 | 93.27 | 82.84 | 87.54 | Upgrade
|
| Research & Development | 67.11 | 57.15 | 45.61 | 52.91 | 47.64 | Upgrade
|
| Operating Expenses | 222.2 | 179.4 | 138.89 | 135.74 | 135.18 | Upgrade
|
| Operating Income | -124.86 | -97.88 | -65.54 | -79.04 | -92.29 | Upgrade
|
| Interest Expense | -15.35 | -12.52 | -14.72 | -8.44 | - | Upgrade
|
| Interest & Investment Income | 5.97 | 8.9 | 2.64 | 0.94 | 0.37 | Upgrade
|
| Other Non Operating Income (Expenses) | -19.17 | -23.64 | -20.71 | -21.49 | -17.44 | Upgrade
|
| EBT Excluding Unusual Items | -153.42 | -125.14 | -98.32 | -108.03 | -109.37 | Upgrade
|
| Other Unusual Items | - | 1.1 | - | - | - | Upgrade
|
| Pretax Income | -153.42 | -124.04 | -98.32 | -108.03 | -109.37 | Upgrade
|
| Income Tax Expense | 0.08 | 2.83 | 3.92 | 1.76 | 1.45 | Upgrade
|
| Net Income | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 | Upgrade
|
| Net Income to Common | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 | Upgrade
|
| Shares Outstanding (Basic) | 48 | 43 | 29 | 23 | 22 | Upgrade
|
| Shares Outstanding (Diluted) | 48 | 43 | 29 | 23 | 22 | Upgrade
|
| Shares Change (YoY) | 12.22% | 48.70% | 26.43% | 2.05% | 2.60% | Upgrade
|
| EPS (Basic) | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 | Upgrade
|
| EPS (Diluted) | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 | Upgrade
|
| Free Cash Flow | -162.73 | -97.06 | -76.57 | -87.81 | -85.64 | Upgrade
|
| Free Cash Flow Per Share | -3.38 | -2.26 | -2.66 | -3.85 | -3.83 | Upgrade
|
| Gross Margin | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% | Upgrade
|
| Operating Margin | -113.73% | -108.28% | -79.23% | -122.82% | -192.11% | Upgrade
|
| Profit Margin | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% | Upgrade
|
| Free Cash Flow Margin | -148.22% | -107.37% | -92.57% | -136.45% | -178.27% | Upgrade
|
| EBITDA | -124.56 | -97.55 | -64.73 | -78.12 | -91.46 | Upgrade
|
| EBITDA Margin | -113.45% | -107.92% | -78.26% | -121.38% | -190.38% | Upgrade
|
| D&A For EBITDA | 0.31 | 0.33 | 0.8 | 0.92 | 0.83 | Upgrade
|
| EBIT | -124.86 | -97.88 | -65.54 | -79.04 | -92.29 | Upgrade
|
| EBIT Margin | -113.73% | -108.28% | -79.23% | -122.82% | -192.11% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.